This study is checking the safety and effects of a new drug called RO7502175 for people with certain advanced cancers. A cancer is a disease where some cells grow uncontrollably and can spread. This study will also see how RO7502175 works alone or with other drugs like atezolizumab or pembrolizumab. These are known as checkpoint inhibitors, which help the immune system fight cancer cells. The study involves two stages: dose escalation, where they find the safest dose, and dose expansion, where more people try the drug to check how well it works.

Key Points:

• The study requires a life expectancy of at least 12 weeks and no recent cancer treatments before joining.
• Pregnant or breastfeeding women, and those with certain infections or conditions, cannot participate.
• Participants must be willing to provide a tumor sample and need to have measurable disease.